Managed Access Programs for PKC412, Midostaurin

NCT05219266 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Aggressive Systemic Mastocytosis
Mast Cell Leukemia
Systemic Mastocytosis With an Associated Hematologic Neoplasm

Interventions

DRUG: midostaurin

Sponsor

Novartis Pharmaceuticals